Cargando…

1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants

BACKGROUND: Children with Epstein–Barr virus (EBV) viremia after hematopoietic stem cell transplantation (HSCT) are at increased risk of post-transplant lymphoproliferative disease (PTLD). Our aim was to assess whether pre-emptive rituximab reduced EBV-viral load (EBV-VL) and the risk of developing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catho, Gaud, Scheel, Daniel, Teira, Pierre, Renaud, Christian, Kakinami, Lisa, Ovetchkine, Philippe, Autmizguine, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254397/ http://dx.doi.org/10.1093/ofid/ofy210.1429

Ejemplares similares

Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab
por: Wei, Na, et al.
Publicado: (2021)

Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Xiu-li, et al.
Publicado: (2012)

P1313: LOW DOSE RITUXIMAB FOR PRE-EMPTIVE TREATMENT OF EPSTEIN BARR VIRUS REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Mei, Chen, et al.
Publicado: (2023)

Epstein–Barr virus seroprevalence and viral load at disease onset in children with inflammatory bowel disease
por: Kornitzer, Gaël, et al.
Publicado: (2022)

Association of Epstein-Barr virus infection with allogeneic hematopoietic stem cell transplantation in patients in Portugal
por: Marinho-Dias, Joana, et al.
Publicado: (2019)

Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis
por: Alabdaljabar, Mohamad S., et al.
Publicado: (2020)

Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes
por: Papalexandri, Apostolia, et al.
Publicado: (2023)

Association Between Cytomegalovirus and Epstein-Barr Virus Co-Reactivation and Hematopoietic Stem Cell Transplantation
por: Li, Shan-shan, et al.
Publicado: (2022)

P1561: HBSAG-POSITIVE PATIENTS WITH CO-REACTIVATION OF CYTOMEGALOVIRUS AND EPSTEIN-BARR VIRUSES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED WITH POOR SURVIVAL
por: Ren, Jinhua, et al.
Publicado: (2023)

Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study
por: Ruan, Yongsheng, et al.
Publicado: (2023)

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
por: Xuan, Li, et al.
Publicado: (2012)

Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
por: Liu, Li, et al.
Publicado: (2020)

Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation
por: Zhou, Jing-Rui, et al.
Publicado: (2021)

Stress-Induced Epstein-Barr Virus Reactivation
por: Sausen, Daniel G., et al.
Publicado: (2021)

Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with Rituximab
por: Smeltzer, Jacob P., et al.
Publicado: (2014)

Epstein–Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non–Hodgkin lymphoma: the prevalence and impacts on outcomes: EBV and CMV reactivation post allo-HCT in NHL
por: Ding, Yiyang, et al.
Publicado: (2021)

Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein–Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Diop, Ndeye Soukeyna, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection
por: Luo, Yanhui, et al.
Publicado: (2022)

Programmed death 1 monoclonal antibody helped to treat mixed chimeric and reactivation of Epstein-Barr virus in a patient with adult-onset chronic active Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation: A case report
por: You, Yahong, et al.
Publicado: (2022)

Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis
por: Kołodziejczak, Michalina, et al.
Publicado: (2021)

Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin
por: Wu, Chung-Chun, et al.
Publicado: (2017)

Epstein-Barr Virus Reactivation Causing Cholestatic Hepatitis
por: Da Cunha, Teresa, et al.
Publicado: (2022)

Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Barkam, Corinna, et al.
Publicado: (2012)

Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation
por: Ainley, Louise, et al.
Publicado: (2020)

Epstein–Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment
por: Magnusson, Mattias, et al.
Publicado: (2010)

Poor relief in England and Wales 1601–1834
Publicado: (1976)

Anticonvulsant Hypersensitivity Syndrome Associated with Epstein-Barr Virus Reactivation
por: Chang, Jae Yong, et al.
Publicado: (2007)

Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus
por: Gorres, Kelly L., et al.
Publicado: (2016)

EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOID MALIGNANCIES: THE EXPANDING SPECTRUM OF HEMATOPOIETIC NEOPLASMS
por: KIMURA, HIROSHI, et al.
Publicado: (2013)

Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Epstein-Barr virus-associated acute disseminated encephalomyelitis successfully treated with rituximab: a case report
por: Kim, Seoyeon, et al.
Publicado: (2021)

P1560: EARLY DIAGNOSIS WITH EBV MONITOR AND PREEMPTIVE RITUXIMAB REDUCES POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER MORTALITY AND INCREASE OVERALL SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION
por: Liu, Jia-Hau, et al.
Publicado: (2023)

A Molecular Link between Malaria and Epstein–Barr Virus Reactivation
por: Chêne, Arnaud, et al.
Publicado: (2007)

Epstein–Barr Virus Reactivation-Induced Immunoglobulin Production: Significance on Autoimmunity
por: Nagata, Keiko, et al.
Publicado: (2020)

Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation
por: Murata, Takayuki, et al.
Publicado: (2021)

REACTIVATION OF EPSTEIN-BARR VIRUS AND CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH COVID-19
por: ALMAGUER, ANGELICA, et al.
Publicado: (2022)

Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients
por: Bernal, Keishanne Danielle E., et al.
Publicado: (2023)

Epstein–Barr virus reactivation‐related meningoencephalitis with transverse myelitis in pregnancy
por: Nguyen, Andrew Dang Khai, et al.
Publicado: (2023)

The mathematical career of Pierre de Fermat: 1601-1665
por: Mahoney, Michael Sean
Publicado: (1994)

The Epstein-Barr Virus
por: Payne, L. N.
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_2m1qqmu7c45uu645o4ktu5mard